Compare LZM & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZM | RGNX |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | Isle of Man | United States |
| Employees | 142 | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.4M | 418.1M |
| IPO Year | N/A | 2015 |
| Metric | LZM | RGNX |
|---|---|---|
| Price | $4.00 | $8.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $7.00 | ★ $28.75 |
| AVG Volume (30 Days) | 306.9K | ★ 605.4K |
| Earning Date | 03-19-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | $86.37 | $50.15 |
| Revenue Next Year | $202.49 | $23.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $2.90 | $5.16 |
| 52 Week High | $6.23 | $16.19 |
| Indicator | LZM | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.77 | 52.47 |
| Support Level | $3.60 | $7.78 |
| Resistance Level | $4.38 | $9.28 |
| Average True Range (ATR) | 0.27 | 0.52 |
| MACD | 0.11 | 0.14 |
| Stochastic Oscillator | 84.68 | 77.35 |
Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining and to become an emerging supplier of responsibly sourced, lower-carbon and lower-sulfur dioxide emission metals to the battery, EV, and hydrogen markets modern pre-development exploration-stage metals company. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.